Glaukos Epioxa Phase 3 Extension Shows Sustained Efficacy, Favorable Safety at Three Years
MT newswire2026/10/07 21:4505:45 PM EDT, 10/07/2026 (MT Newswires) -- Glaukos (GKOS) said late Wednesday a long-term Phase 3 extension study of Epioxa, its corneal cross-linking treatment for keratoconus, showed sustained efficacy and a favorable safety profile three years after a single treatment. The study followed patients treated in Epioxa's second Phase 3 pivotal trial. Treated eyes showed a sustained 1.9-diopter (D) improvement in maximum corneal curvature from baseline, indicating corneal flattening and stabilization, the company said. No additional intervention occurred during the extension period. At year three, 29% of treated eyes gained at least two lines of best-corrected visual acuity from baseline, while 20% gained at least three lines. No serious adverse events, treatment-related adverse events or discontinuations due to adverse events were reported through three years, the medical technology company said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Boston Fed President Collins: Gradual rate hikes are appropriate; a stable labor market has not pushed up prices.
Boston Federal Reserve President Collins stated that, with the labor market stabilizing and not putting additional pressure on prices, a gradual approach to interest rate hikes would be an appropriate path to reduce inflation.
McDonald's in Lugano, Switzerland supports Bitcoin Lightning Network payments
Polkadot will allow locking DOT to mint dotUSD in the future.
Crypto prices
More
